Technology
Lab Automation Market to Reach $11.31 Billion by 2031, Driven by Rising Pharmaceutical & Biotech R&D Expenditures and Increasing Demand for Automated Laboratories and Instruments – Report by Meticulous Research®
Published
2 months agoon
By
REDDING, Calif., Sept. 16, 2024 /PRNewswire/ — According to a new market research report titled, ‘Lab Automation Market Size, Share, Forecast, & Trends Analysis by Product (Liquid Handling, Nucleic Acid Purification System, Microplate Reader, ELISA, LIMS, ELN), Application (Drug Discovery, Diagnostics, Genomics),End User—Global Forecast to 2031.
The lab automation market is projected to reach $11.31 billion by 2031, at a CAGR of 7.3% from 2024 to 2031.
Download FREE PDF Brochure Of Lab Automation Market – https://www.meticulousresearch.com/pressrelease/967/lab-automation-market-2031
Rising pharmaceutical and biotech R&D expenditures, the increasing demand for automated laboratories and instruments, the high prevalence of chronic and infectious diseases, and initiatives supporting life sciences R&D are driving the growth of the lab automation market. However, the high costs of advanced lab automation equipment and funding & infrastructure limitations in developing countries are factors restraining the growth of this market.
Furthermore, growth in genomics & proteomics research, the increasing focus on food safety & quality, rising awareness & growing adoption of personalized medicines, and emerging economies are expected to generate growth opportunities for the players operating in the lab automation market. However, equipment maintenance & repair and data security & privacy concerns are major challenges impacting market growth.
Get Insightful Data On Regions, Market Segments, Customer Landscape, And Top Companies (Charts, Tables, Figures And More) – https://www.meticulousresearch.com/download-sample-report/cp_id=1221
Automated Laboratories: Effective Management of Clinical Workflows
Lab automation is being widely adopted in clinical laboratories to increase accuracy and efficiency and reduce costs and errors. In the field of medicine, a diagnostic error can incur very high costs. Hence, automating clinical laboratories can significantly reduce human errors and associated costs.
Automating clinical laboratories can have a positive impact on patient outcomes. Quick and reliable diagnostic results allow medical professionals to initiate appropriate treatments, improving the chances of patient survival. Additionally, limited resources, long waiting times for diagnostic results, and the shortage of skilled laboratory staff can lead to poor patient outcomes. The implementation of lab automation in clinical laboratories helps mitigate these issues and provides quick and reliable results, improving patient outcomes.
In the U.S., an estimated 10–20% of diagnoses are inaccurate and result in 40,000–80,000 deaths each year. Automation improves the ordering, testing, and reporting of diagnostic tests and ensures higher throughput, increased productivity, efficient use of reagents & materials, and standardization, decreasing errors and improving turnaround times.
Browse In-depth Report Now – https://www.meticulousresearch.com/product/lab-automation-market-1221
The players operating in this market are focused on launching new automated diagnostic instruments. For instance:
In May 2024, Abbott Laboratories (U.S.) launched its GLP Systems Track in India to support the high-volume needs of laboratories.In September 2023, Yourgene Health plc (U.K.) launched the Yourgene MagBench Automated DNA Extraction Instrument and Kit for Noninvasive Prenatal Testing (NIPT) workflows.In June 2023, Becton, Dickinson and Company (U.S.) launched its BD FACSDuet Premium Sample Preparation System for cellular diagnostic applications.In January 2023, QIAGEN N.V. (Netherlands) launched the EZ2 Connect MDx Platform for automated sample processing in diagnostic labs.In May 2022, Becton, Dickinson and Company (U.S.) launched BD COR MX, a fully automated, high-throughput infectious disease molecular diagnostics platform.
Lab Automation Market Analysis: Key Segmental Findings
By Product: In 2024, the systems segment is expected to account for the major share of 71.5% of the lab automation market. However, the software segment is expected to grow at the fastest CAGR of 7.4% during the forecast period of 2024–2031.By Application: In 2024, the drug discovery segment is expected to account for the largest share of the market. However, the clinical diagnostics segment is expected to grow at the fastest CAGR during the forecast period of 2024–2031.By End User: In 2024, the pharmaceutical & biotechnology companies’ segment is expected to account for the largest share of 41.0% of the global market.
Explore the Key Market Segments Driving Growth (Download Free Sample) – https://www.meticulousresearch.com/download-sample-report/cp_id=1221
Geographic Analysis:
North America Dominates the Global Market
North America is expected to account for the largest share of 40.8% of the lab automation market. In terms of value, in 2024, the U.S. is expected to account for the major share of 92% of the lab automation market in North America. Pharmaceutical companies in the U.S. are at the forefront of adopting cutting-edge technologies, with a strong emphasis on the implementation of lab automation systems to enhance operational efficiency and gain a competitive edge in the pharmaceutical sector. The adoption of lab automation technologies is driven by several factors, including the surging need for high-throughput analysis, increasing investments in research and development, laboratories’ growing need for increased efficiency, precision, and productivity, and the increasing focus on genomics research and genetic testing. These dynamics are boosting the adoption of lab automation across the country. The U.S. has low market barriers for developing and commercializing pharmaceuticals due to the supportive domestic environment. With the availability of government funding for research activities, robust capital markets, and strong academic research in the country, the U.S. is the world’s largest scientific research base, attracting most global venture capital investments in the biotechnology industry.
Asia-Pacific to Witness Rapid Growth
Asia-Pacific is expected to record the fastest growth over the forecast period, with the regional market reaching $2.74 billion by 2031. The high growth of this regional market is driven by the expanding pharmaceutical & biotechnology industries, rapidly improving healthcare infrastructure, growth in pharmaceutical research, and increasing government funding in APAC. The Asia-Pacific region has become one of the most attractive markets for healthcare & life sciences companies worldwide, primarily due to changing demographics and accelerated economic growth in the region. Countries such as China, India, South Korea, and Indonesia are expanding their healthcare infrastructure, driving the demand for laboratory automation.
Have specific research needs? Request a customized research report – https://www.meticulousresearch.com/request-customization/cp_id=1221
In 2024, China is expected to account for the largest share of the lab automation market in Asia-Pacific. The country’s large market share is mainly attributed to government initiatives focusing on research and development, increasing R&D expenditures of pharmaceutical and biopharmaceutical companies, favorable regulatory policies, the rising prevalence of infectious & chronic diseases, the rising geriatric population, and the increased demand for lab automation among clinical laboratories due to increased disease prevalence.
Germany Continues to Dominate the Lab Automation Market in Europe
In 2024, Germany is expected to account for the largest share of the lab automation market in Europe. Factors such as increasing government investments in the pharmaceutical industry, growing biotech & pharmaceutical R&D expenditures, rising healthcare spending, increasing sample volumes in laboratories due to the rising incidence of chronic and infectious diseases, the increased demand for precision medicines, and the rising focus on genomics research contribute to the country’s largest market share. Germany has a favorable environment for developing and producing research-intensive, high-grade products. According to German Trade & Invest, in 2021, the pharmaceutical industry in Germany invested over $9.1 billion (€7.7 billion) in research and development. Additionally, the government and funding organizations have pledged to substantially increase public & private R&D spending and researchers by 2030 as part of the country’s Sustainable Development Goals (SDG). Thus, increasing government funding for research, the wide availability of technologically advanced laboratory informatics solutions, and laboratories’ need to reduce errors, and associated costs are expected to drive the growth of the lab automation market in Germany.
Need Insights on Regional Data? Check Out Our Detailed Analysis (Download Free Sample) – https://www.meticulousresearch.com/download-sample-report/cp_id=1221
Lab Automation Market: Competition Analysis
This report offers a competitive analysis based on an extensive assessment of the leading players’ product portfolios, geographic presence, and key growth strategies adopted over the past 3–4 years. Major companies in the lab automation market have implemented various strategies to expand their product offerings and global footprints and augment their market shares. The key strategies followed by most companies in the lab automation market include product launches, product enhancements, approvals, partnerships, collaborations, agreements, acquisitions, and expansions. The key players operating in the lab automation market include Thermo Fisher Scientific, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), Revvity, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Waters Corporation (U.S.), Tecan Group Ltd. (Switzerland), F. Hoffmann-La Roche AG (Switzerland), Siemens Healthineers AG (Germany), Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), Hudson Robotics, Inc. (U.S.), and Hamilton Company (U.S.).
Learn About the Top Companies Influencing Market Dynamics (Download Free Sample) – https://www.meticulousresearch.com/download-sample-report/cp_id=1221
Lab Automation Industry Overview: Latest Developments from Key Industry Players
In July 2024, INPECO SA (Switzerland) launched FlexLab X, a next-generation total lab automation system (TLA), at the Annual Scientific Meeting of the Association for Diagnostics & Laboratory Medicine (ADLM 2024). This system can combine analyzers from different vendors, enable space-saving layouts, offers a sleek graphical user interface, and streamlines workflows.In February 2024, Carbon, Inc. (U.S.) launched its Automatic Operation (AO) suite of solutions designed to meet the needs of dental labs, setting new standards in lab automation.In September 2023, Bio-Rad Laboratories, Inc. launched the PTC Tempo 48/48 and PTC Tempo 384 thermal cyclers that are designed to aid PCR applications such as sequencing, cloning, and genotyping.In August 2023, F. Hoffmann-La Roche Ltd launched the Cobas Connection Modules (CCM) sample conveyor systems to enable flexibility in laboratory designs.In July 2023, Agilent Technologies, Inc. launched the BioTek Gen6 Software, which is used for all BioTek detection instruments. This software also provides an intuitive user interface that offers complete control of BioTek microplate readers for absorbance, fluorescence, and luminescence measurements for endpoint and kinetic assays.In July 2023, Thermo Fisher Scientific, Inc. launched the Diomni Enterprise Software, which provides a digital platform to support testing workflows in order to accommodate rapidly evolving needs.In July 2023, Bio-Rad Laboratories launched the IH-500TM NEXT System, a fully automated system for use with Bio-Rad’s ID Cards for routine testing and specialized testing such as newborn screening.In February 2023, Revvity, Inc. launched the EnVision Nexus Multimode Microplate Reader, which provides high-throughput screening and accelerates drug discovery results.In February 2023, Beckman Coulter Life Sciences collaborated with Sciex (U.S.) to provide comprehensive workflows for high-throughput screening HT-ADME and synthetic biology studies. The Echo MS System, which is based on Sciex’s Acoustic Ejection Mass Spectrometry technology, is now compatible with Beckman’s Echo Liquid Handlers.In February 2023, Tecan Group Ltd. collaborated with Element Biosciences, Inc. (U.S.) to offer a true benchtop NGS workflow with the MagicPrep NGS and AVITI System. This collaboration was aimed at enabling the direct conversion of NGS libraries without affecting sample quality.In June 2022, Beckman Coulter Life Sciences launched the Biomek NGeniuS liquid handling system to automate the labor-intensive process of manual library construction and reagent transfers. The system also eliminates loading errors.In April 2022, Revvity, Inc. collaborated with Scitara Corporation (U.S.) to integrate PerkinElmer’s Signals Research Suite informatics platform and Scitara’s iPaaS universal connectivity solution to facilitate fully connected laboratories along with standard data integrity, data mobility, system flexibility, and user reconfigurability.
The report provides a competitive dashboard summarizing the market positioning of the 20 profiled market players in four quadrants, namely Industry Leaders, Differentiators, Emerging Companies, and Vanguards. These companies are positioned based on various parameters, including revenue, depth of offerings, brand equity, geographic presence, innovation, and organic & inorganic growth strategies. Thermo Fisher Scientific, Inc. (U.S), Danaher Corporation (U.S.), F. Hoffmann-La Roche AG (Switzerland), Hamilton Company (U.S.), Abbott Laboratories (U.S.), and Siemens Healthineers AG (Germany) are positioned in the industry leaders quadrant.
IMMEDIATE DELIVERY AVAILABLE | BUY THIS RESEARCH REPORT (Insights, Charts, Tables, Figures and More)- https://www.meticulousresearch.com/Checkout/13937383
Scope of the Report:
Lab Automation Market Assessment–by Product
SystemsAutomated Liquid Handling SystemsAutomated Nucleic Acid Purification SystemsAutomated ELISA SystemsAutomated Microplate ReadersAutomated Storage & Retrieval SystemsOther Lab Automation SystemsSoftwareLaboratory Information Management Systems (LIMS)Electronic Lab Notebook (ELN)Workstation/Equipment Automation SoftwareScientific Data Management Systems (SDMS)
Lab Automation Market Assessment–by Application
Drug DiscoveryClinical DiagnosticsGenomics & Proteomics ResearchOther Applications
(Note: Other applications include bioprocessing in biotechnology, cell analysis, basic research, forensic analysis, and quality control in the F&B industry.)
Lab Automation Market Assessment–by End User
Pharmaceutical & Biotechnology CompaniesHospitals & Diagnostic LaboratoriesAcademic & Research InstitutesOther End Users
(Note: Other end users include the food & agriculture industries, forensic laboratories, blood banks, and environmental & quality testing laboratories.)
Lab Automation Market Assessment–by Geography
North AmericaU.S.CanadaEuropeGermanyU.K.FranceItalySpainRest of Europe (RoE)Asia-Pacific (APAC)ChinaJapanIndiaRest of APAC (RoAPAC)Latin AmericaMiddle East & Africa
Browse More Related Reports:
Lab Automation Market is projected to hit $11.31 billion by 2031, growing at CAGR of 7.3% from 2024. Discover trends and growth factors driving this sector. – https://www.meticulousresearch.com/product/lab-automation-market-1221
Clinical Lab Automation Market is expected to reach $4.01 billion by 2031, at a CAGR of 7.8% from 2024 to 2031. – https://www.meticulousresearch.com/product/clinical-lab-automation-market-5762
Electronic Lab Notebook Market is expected to grow at a CAGR of 7.1% to reach $787.7 million by 2029. – https://www.meticulousresearch.com/product/electronic-lab-notebook-eln-market-4341
NGS Automation Market is expected to grow at a CAGR of 13.4% from 2022–2029 to reach $1.33 billion by 2029. – https://www.meticulousresearch.com/product/ngs-automation-market-5271
Explore future of Industrial Automation Software Market, projected to hit $59.5 billion by 2029. – https://www.meticulousresearch.com/product/industrial-automation-software-market-5279
Pharmaceutical Automation Market, valued at $11.16 Bn in 2023, is projected to reach $25.11 Bn by 2031, growing at a 10.8% CAGR from $12.21 Bn in 2024. – https://www.meticulousresearch.com/product/pharmaceutical-automation-market-5280
Lab-grown Meat Market is projected to reach $1.99 billion by 2035, at a CAGR of 21.4% during forecast period of 2025–2035. – https://www.meticulousresearch.com/product/lab-grown-meat-market-5293
North America Electronic Lab Notebooks Market is projected to reach $372.7 million by 2030, at a CAGR of 6.8% from 2024 to 2030. – https://www.meticulousresearch.com/product/north-america-electronic-lab-notebook-market-5604
Europe Electronic Lab Notebook (ELN) Market is projected to reach $264.3 million by 2030, at a CAGR of 7% from 2024 to 2030. – https://www.meticulousresearch.com/product/europe-electronic-lab-notebook-market-5683
Pharmacy Automation Market is expected to reach $7.87 billion by 2030, at a CAGR of 7.6% during forecast period 2024–2030. – https://www.meticulousresearch.com/product/pharmacy-automation-market-5700
Life science equipment market is projected to reach $97.96 billion by 2031, at a CAGR of 6.3% from 2024 to 2031 – https://www.meticulousresearch.com/product/life-science-equipment-market-3937
Europe NGS automation Market to be worth $380.4 million by 2030, growing at a 13.4% CAGR from 2024 to 2030. – https://www.meticulousresearch.com/product/europe-ngs-automation-market-5644
North America NGS Automation Market is expected to reach $776.1 million by 2030, at a CAGR of 14% during forecast period 2024–2030 – https://www.meticulousresearch.com/product/north-america-ngs-automation-market-5736
Asia-Pacific NGS Automation Market is expected to reach $371 million by 2031 at a CAGR of 16.3% from 2024 to 2031 – https://www.meticulousresearch.com/product/asia-pacific-ngs-automation-market-5790
Lab Automation Market Research Summary
Particular
Details
Page No
244
Format
Forecast Period
2024-2031
Base Year
2023
CAGR
7.30 %
Market Size (Value)
$11.31 billion
Market Size (Volume)
NA
Countries Covered
North America (U.S., Canada), Europe (Germany, France, U.K., Italy, Spain, RoE), Asia-Pacific (China, Japan, India, RoAPAC), Latin America, and the Middle East & Africa.
Key Companies
Thermo Fisher Scientific, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), Revvity, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Waters Corporation (U.S.), Tecan Group Ltd. (Switzerland), F. Hoffmann-La Roche AG (Switzerland), Siemens Healthineers AG (Germany), Abbott Laboratories (U.S.), Becton, Dickinson, and Company (U.S.), Hudson Robotics, Inc. (U.S.), Hamilton Company (U.S.)
Click here to: Get Free Sample Pages of this Report
Hot Industry Reports: Emerging Trends and Market Forecasts
Veterinary Practice Management Software Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/veterinary-practice-management-software-market-1432
Asia Pacific Orthodontics Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/asia-pacific-orthodontics-market-4978
Feed Software Market by Size, Share, Forecast, & Trends Analysis – https://www.meticulousresearch.com/product/feed-software-market-2639
Point-of-care Diagnostics Market Size & Trends Analysis 2030 – https://www.meticulousresearch.com/product/point-of-care-diagnostics-market-4871
Soluble Dietary Fibers Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/soluble-dietary-fibers-market-3953
Genomics Market: Size, Trends & Global Forecast to 2031 – https://www.meticulousresearch.com/product/genomics-market-1262
Healthcare Gamification Market Size, Share, & Growth 2030 – https://www.meticulousresearch.com/product/healthcare-gamification-market-2592
3D Cell Culture Market Size & Growth Insights 2024-2030 – https://www.meticulousresearch.com/product/3d-cell-culture-market-1246
South East Asia Collagen Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/south-east-asia-collagen-market-3634
Next Generation Sequencing Informatics (NGS) Market Size, Share, Forecast, & Trends Analysis – https://www.meticulousresearch.com/product/ngs-informatics-market-3483
Recombinant Coagulation Factors Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/recombinant-coagulation-factors-market-1254
Crop Protection Chemicals Market Size, Share, Report, & Trends 2031 – https://www.meticulousresearch.com/product/crop-protection-chemicals-market-2584
Integrated Pest Management (IPM) Pheromones Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/integrated-pest-management-pheromones-market-5211
Sports Medicine Market: Size, Share, Forecast & Trends – https://www.meticulousresearch.com/product/sports-medicine-market-1215
MRI Infrastructure Capacity Assessment by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/mri-infrastructure-capacity-assessment-1217
Digital X-ray Systems Market Size, Share, Forecast, & Trends – https://www.meticulousresearch.com/product/digital-x-ray-systems-market-1183
Sports Technology Market Size, Trends & Forecast to 2030 – https://www.meticulousresearch.com/product/sports-technology-market-5584
Home Healthcare Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/home-healthcare-market-1280
Next Generation Sequencing Market Size, Share & Trends 2023-2030 – https://www.meticulousresearch.com/product/next-generation-sequencing-market-5040
Cloud Analytics Market Insights: Size, Share & Trends – https://www.meticulousresearch.com/product/cloud-analytics-market-5208
Home Medical Equipment Market by Size, Share, Forecast, & Trends Analysis – https://www.meticulousresearch.com/product/home-medical-equipment-market-1284
IoT in Healthcare Market Size, Share, & Trends 2031 – https://www.meticulousresearch.com/product/iot-in-healthcare-market-4945
Surgical Sutures Market by Size, Share, & Trends 2030 – https://www.meticulousresearch.com/product/surgical-sutures-market-4947
Lab Automation Market: Share, Trends & Forecast Analysis – https://www.meticulousresearch.com/product/lab-automation-market-1221
Asia Pacific EV Battery Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/asia-pacific-ev-battery-market-5217
Medical Imaging Market: Products, Applications, & Forecasts – https://www.meticulousresearch.com/product/medical-imaging-market-4950
Medical Ceramics Market by Size, Share, Forecast, & Trends Analysis – https://www.meticulousresearch.com/product/medical-ceramics-market-5538
Pharmaceutical Packaging Market Size, & Trends 2031 – https://www.meticulousresearch.com/product/pharmaceutical-packaging-market-5298
Ultrasound Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/ultrasound-market-4972
Tissue Diagnostics Market Insights: Size, Trends & Forecast – https://www.meticulousresearch.com/product/tissue-diagnostics-market-4971
Contact:
Mr. Khushal Bombe
Meticulous Market Research Inc.
1267 Willis St, Ste 200 Redding,
California, 96001, U.S.
USA: +1-646-781-8004
Europe: +44-203-868-8738
APAC: +91 744-7780008
Email- sales@meticulousresearch.com
Visit Our Website: https://www.meticulousresearch.com/
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Meticulousblog.org | Top Market Research Reports Blog – https://meticulousblog.org/
Content Source: https://www.meticulousresearch.com/pressrelease/967/lab-automation-market
Photo: https://mma.prnewswire.com/media/2506511/Lab_Automation_Market.jpg
Logo: https://mma.prnewswire.com/media/1757980/Meticulous_Research_Logo_1.jpg
You may like
Technology
Nuvilab: Advancing School Nutrition with AI-Powered Nutrition Coaching, Wins CES 2025 Innovation Award
Published
1 minute agoon
November 15, 2024By
SEOUL, South Korea, Nov. 15, 2024 /PRNewswire/ — Nuvilab announced that its innovative AI nutrition coaching solution, NutriTrex, was awarded the CES 2025 Innovation Award in the Digital Health category. This prestigious honor highlights Nuvilab’s groundbreaking approach to promoting healthy eating habits among children and adolescents, marking its third CES Innovation Award following recognition in 2021 for Digital Health and Sustainability advancements.
The AI nutrition coaching solution seamlessly integrates into schools and daycare centers, using AI to provide real-time feedback and personalized suggestions for children’s meals. By engaging children, teachers, and parents in a collaborative environment, Nuvilab empowers young learners to build lasting healthy eating habits. The platform not only tracks meal patterns but also offers actionable insights to support lifelong wellness, making healthy eating both fun and interactive.
CEO Logan Kim stated, “We are honored to see our solution recognized on the global stage. Nuvilab’s technology is transforming school nutrition environments in Korea and beyond, fostering healthier habits in children and creating meaningful impacts on their lifelong well-being. This award reaffirms our commitment to expanding our mission worldwide.”
With this CES accolade, Nuvilab is poised to accelerate its expansion into North America and other global markets. The company is actively collaborating with international clients in the food service sector, with plans to extend its reach into areas where nutrition management is essential.
View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvilab-advancing-school-nutrition-with-ai-powered-nutrition-coaching-wins-ces-2025-innovation-award-302306948.html
SOURCE Nuvilab
Technology
MDA SPACE REPORTS THIRD QUARTER 2024 RESULTS
Published
1 minute agoon
November 15, 2024By
Q3 2024 Highlights Significant backlog of $4.6 billion at quarter-end, up 49% YoYStrong top line growth with revenues of $282.4 million, up 38% YoYSolid profitability with adjusted EBITDA1 of $55.5 million, up 30% YoY, and adjusted EBITDA margin1 of 19.7%Solid adjusted net income1 of $34.7 million, up 60% YoY, and adjusted diluted earnings per share1 of $0.28, up 56% YoY Strong operating cash flow of $258.8 millionNet debt to adjusted EBITDA1 ratio of 0.8x at quarter-end Updated 2024 full-year financial outlookRaised revenue guidance, narrowed adjusted EBITDA guidance and reaffirmed capital expenditures guidanceReaffirmed positive free cash flow in 2024
BRAMPTON, ON, Nov. 15, 2024 /PRNewswire/ – MDA Space Ltd. (TSX: MDA), a trusted space mission partner to the rapidly expanding global space industry, today announced its financial results for the third quarter ended September 30, 2024.
“In Q3, the MDA Space team delivered another strong quarter with double digit growth in our top and bottom lines as we continued to execute and convert our backlog,” said Mike Greenley, Chief Executive Officer of MDA Space.
“The team continued to execute on our major programs, successfully conducting the preliminary design review for the Canadarm3 program, a critical milestone for the program. We also made significant progress on MDA CHORUS™, our next generation Earth Observation constellation, completing the spacecraft assembly and commencing spacecraft integration and testing. And in our Satellite Systems business, the team made solid progress advancing the engineering work for the Telesat Lightspeed program. In Q3, we also broke ground on our Satellite Systems facility expansion in Quebec which will add 185,000 square feet of advanced manufacturing capacity,” continued Mr. Greenley.
“I am also pleased to welcome Guillaume Lavoie to the MDA Space Team as Chief Financial Officer. Guillaume brings a wealth of financial leadership experience and will be instrumental in supporting our long-term growth plans and helping us deliver successfully for our customers and shareholders.”
Q3 2024 HIGHLIGHTS
Backlog of $4.6 billion at quarter-end provides good revenue visibility for 2025 and beyond and was up 49% compared to Q3 2023. The year-over-year increase in backlog is driven by new order bookings including the $1 billion award for Phases C/D of the Canadarm3 program announced in Q2 2024.Revenues of $282.4 million in Q3 2024 were up 38.0% year-over-year driven by higher work volumes across the business with strong contributions from the Satellite Systems and Robotics & Space Operations businesses.Adjusted EBITDA of $55.5 million in Q3 2024 compared to $42.8 million in Q3 2023, representing an increase of $12.7 million (or 29.7%) year-over-year. Adjusted EBITDA margin of 19.7% in Q3 2024 is consistent with the Company’s full year margin guidance of 19-20% and compares to adjusted EBITDA margin of 20.9% reported in the third quarter of 2023.Adjusted net income for Q3 2024 was $34.7 million compared to $21.7 million in Q3 2023, representing an increase of $13.0 million (or 59.9%) year-over-year driven by higher operating income. Adjusted diluted earnings per share of $0.28 in Q3 2024 compared to $0.18 in Q3 2023, representing an increase of 55.6% year-over-year.Operating cash flow was $258.8 million in Q3 2024 compared to $(30.0) million in Q3 2023. The year-over-year increase in operating cash flow was driven by positive working capital contributions primarily related to the Telesat Lightspeed program.At quarter-end, net debt to adjusted EBITDA ratio was 0.8x compared to 2.4x as of December 2023 (2.0x as of June 30, 2024) as the Company utilized its strong operating cash flow in Q3 2024 to make repayments to its revolving credit facility and deleverage the balance sheet while continuing to invest in its growth initiatives.
_______________________
1 As defined in the “Non-IFRS Financial Measures” section
2024 FINANCIAL OUTLOOK
As a trusted mission partner and leading global space technology provider, we are leveraging our capabilities and expertise to execute on targeted growth strategies across our end markets and business areas. Our strategic initiatives, which span across our three businesses, include investing in next generation space technology and services, expanding our presence in high growth markets and geographies, scaling and expanding skills, talent and operations to meet current and future market demand and leveraging strategic M&A to complement organic growth. We continue to make good progress against our long-term strategic plan.
MDA Space is well positioned to capitalize on strong customer demand and robust market activity given our diverse and proven technology offerings. Our growth pipeline is significant and underpinned by existing and new programs and our book of business is healthy. We see activities ramping up in line with our expectations and are encouraged by the team’s solid execution.
For fiscal 2024, we are raising our full year revenue guidance to $1,045 – $1,065 million from $1,020 – $1,060 million previously, representing robust year-over-year growth of approximately 30% at the mid-point of guidance compared to 2023 levels. We are narrowing our full year adjusted EBITDA range to $205 – $210 million from $200 – $210 million previously, representing approximately 19% – 20% adjusted EBITDA margin. We reaffirm our expectations that capital expenditures will be $200 – $220 million, comprising primarily growth investments to support CHORUS and the previously outlined growth initiatives across our three business areas. We continue to expect favourable working capital contributions related to the Telesat Lightspeed program to result in positive free cash flow in 2024 allowing us to continue to deleverage our balance sheet
FINANCIAL OVERVIEW
KEY INDICATORS SUMMARY
Third Quarters Ended
Nine Months Ended
(in millions of Canadian dollars, except per share data)
Sept. 30, 2024
Sept. 30, 2023
Sept. 30, 2024
Sept. 30, 2023
Revenues
$
282.4
$
204.7
$
733.5
$
602.6
Gross profit
$
75.7
$
57.7
$
199.8
$
186.2
Gross margin
26.8 %
28.2 %
27.2 %
30.9 %
Adjusted EBITDA2
$
55.5
$
42.8
$
146.2
$
132.1
Adjusted EBITDA margin2
19.7 %
20.9 %
19.9 %
21.9 %
Adjusted Net Income2
$ 34.7
$ 21.7
$ 76.0
$ 70.1
Adjusted Diluted EPS2
$ 0.28
$ 0.18
$ 0.61
$ 0.58
As at
(in millions of Canadian dollars, except for ratios)
September 30, 2024
December 31, 2023
Backlog
$
4,578.1
$
3,097.0
Net debt2 to Adjusted TTM3 EBITDA ratio
0.8x
2.4x
REVENUES BY BUSINESS AREA
Third Quarters Ended
Nine Months Ended
(in millions of Canadian dollars)
Sept. 30, 2024
Sept. 30, 2023
Sept. 30, 2024
Sept. 30, 2023
Geointelligence
$
48.3
$
48.4
$
154.7
$
147.6
Robotics & Space Operations
66.5
61.9
215.1
183.5
Satellite Systems
167.6
94.4
363.7
271.5
Consolidated revenues
$
282.4
$
204.7
$
733.5
$
602.6
Revenues
Consolidated revenues for the third quarter of 2024 were $282.4 million, representing an increase of $77.7 million (or 38.0%) from the third quarter of 2023. The year-over-year increase in revenues was driven by higher work volumes across our business, with strong contributions from our Satellite Systems and Robotics & Space Operations businesses.
By business area, revenues in Geointelligence for the third quarter of 2024 were $48.3 million, which represents a decrease of $0.1 million (or 0.2%) from the same period in 2023 reflecting steady work volumes. Revenues in Robotics & Space Operations for the third quarter of 2024 were $66.5 million, which represents an increase of $4.6 million (or 7.4%) from the same period in 2023. The year-over-year increase is primarily driven by higher volume of work performed on the Canadarm3 program. Revenues in Satellite Systems for the third quarter of 2024 were $167.6 million, which represents an increase of $73.2 million (or 77.5%) from the same period in 2023 driven by higher contributions in the latest quarter from new programs including Telesat Lightspeed and the authorization to proceed (ATP) for an undisclosed customer for a NGSO satellite constellation (announced in Q4 2023).
Consolidated revenues for the nine months ended September 30, 2024 were $733.5 million, representing an increase of $130.9 million (or 21.7%) from the same period of 2023. The year-over-year increase in revenues was primarily driven by increased work volume from our Satellite Systems and Robotics & Space Operations businesses.
By business area, revenues in Geointelligence for the first nine months of 2024 were $154.7 million, which represents an increase of $7.1 million (or 4.8%) from the same period in 2023 reflecting higher work volume on CSC and other new programs in 2024. Revenues in Robotics & Space Operations for the first nine months of 2024 were $215.1 million, which represents an increase of $31.6 million (or 17.2%) from the same period in 2023. The year-over-year increase is primarily driven by the higher volume of work performed on the Canadarm3 program. Revenues in Satellite Systems for the first nine months of 2024 were $363.7 million, which represents an increase of $92.2 million (or 34.0%) from the same period in 2023 driven by higher contributions from new programs including the Telesat Lightspeed program and the ATP for an undisclosed customer for a NGSO satellite constellation.
________________________
2 As defined in the “Non-IFRS Financial Measures” section
3 TTM: Trailing twelve months
Gross Profit and Gross Margin
Gross profit reflects our revenues less cost of revenues. Q3 2024 gross profit of $75.7 million represents a $18.0 million (or 31.2%) increase over Q3 2023 driven by higher work volume in the current quarter. Gross margin in Q3 2024 was 26.8%, which is in line with the Company’s expectations and compares to gross margin of 28.2% in Q3 2023. The year- over-year change in gross margin is driven by evolving program mix and higher depreciation expense as new assets come into service.
For the nine months ended September 30, 2024, gross profit of $199.8 million represents a $13.6 million (or 7.3%) increase over 2023 levels. Gross margin for the nine months ended September 30, 2024 was 27.2% which is in line with the Company’s expectations and compares to 30.9% for the same period in 2023. The year-over-year change in gross profit and gross margin metrics is driven by evolving program mix and higher depreciation expense as new assets come into service.
Adjusted EBITDA and Adjusted EBITDA Margin
Adjusted EBITDA for the third quarter of 2024 was $55.5 million compared with $42.8 million for the third quarter of 2023, representing an increase of $12.7 million (or 29.7%) year-over-year driven by higher volume of work and steady operating expenses. Adjusted EBITDA margin of 19.7% for the third quarter of 2024 is consistent with the Company’s full year margin guidance of 19-20% and compares to adjusted EBITDA margin of 20.9% reported in the third quarter of 2023.
Adjusted EBITDA for the nine months ended September 30, 2024 was $146.2 million compared with $132.1 million for the same period in 2023, representing an increase of $14.1 million (or 10.7%) year-over-year. The improvement was driven by higher volumes of work performed year-over-year somewhat offset by program mix. Adjusted EBITDA margin was 19.9% for the nine months ended September 30, 2024 compared with 21.9% for the same period in 2023.
Adjusted Net Income
Adjusted net income for the third quarter of 2024 was $34.7 million compared with $21.7 million for the third quarter of 2023, representing an increase of $13.0 million (or 59.9%) year-over-year driven by higher operating income in the latest quarter.
Adjusted net income for the nine months ended September 30, 2024 was $76.0 million compared with $70.1 million for the same period in 2023, representing a increase of $5.9 million (or 8.4%) year-over-year driven by the aforementioned gross profit variance.
Backlog
Backlog is comprised of our remaining performance obligations which represent the transaction price of firm orders less inception to date revenue recognized and excludes unexercised contract options and indefinite delivery or indefinite quantity contracts. Backlog as at September 30, 2024 was $4,578.1 million, an increase of $1,509.4 million compared with the backlog at September 30, 2023 driven by new order bookings, partially offset by continued conversion of our backlog into revenue. The following table shows the build up of backlog for Q3 2024 as compared with the same period in 2023.
Third Quarters Ended
Nine Months Ended
(in millions of Canadian dollars)
Sept. 30, 2024
Sept. 30, 2023
Sept. 30, 2024
Sept. 30, 2023
Opening Backlog
$
4,596.0
$
1,098.3
$
3,097.0
$
1,378.2
Less: Revenue recognized
(282.4)
(204.7)
(733.5)
(602.6)
Add: Order Bookings
264.5
2,175.1
2,214.6
2,293.1
Ending Backlog
$
4,578.1
$
3,068.7
$
4,578.1
$
3,068.7
CONFERENCE CALL AND WEBCAST
MDA Space will host a conference call and webcast to discuss these financial results on Friday, November 15, 2024 at 8:30 a.m. ET. Interested parties can join the call by dialing 416-764-8609 (Toronto area) or 1-888-390-0605 (toll-free North America) or +44-800-652-2435 (toll-free United Kingdom) and entering the conference ID 94799731. A live webcast of the conference call and an accompanying slide presentation will be available at https://mda-en.investorroom.com/events-presentations.
A replay of the conference will be archived on the MDA Space website following the call. Parties may also access a recording of the call which will be available until November 22, 2024, by dialing 1-888-390-0541 and entering the passcode 799731 #.
NON-IFRS FINANCIAL MEASURES
This press release refers to certain non-IFRS measures. These measures are not recognized measures under IFRS, do not have a standardized meaning prescribed by IFRS and therefore may not be comparable to similar measures presented by other companies. Rather, these measures are provided as additional information to complement those IFRS measures by providing further understanding of our results of operations from management’s perspective. Accordingly, the measures should not be considered in isolation nor as a substitute for analysis of our financial information reported under IFRS. We use non-IFRS measures, including EBITDA, Adjusted EBITDA, Adjusted EBITDA margin, Adjusted Net Income, Adjusted Earnings per Share, Order Bookings, Net Debt and Free Cash Flow, to provide investors with supplemental measures of our operating performance and thus highlight trends in our core business that may not otherwise be apparent when relying solely on IFRS measures. We define EBITDA as net income (loss) before: i) depreciation and amortization expenses, ii) provision for (recovery of) income taxes, and iii) finance costs. Adjusted EBITDA is calculated by adding to and deducting from EBITDA, as applicable, certain expenses, costs, charges or benefits incurred in such period which in management’s view are either not indicative of underlying business performance or impact the ability to assess the operating performance of our business, including i) unrealized foreign exchange gain or loss ii) unrealized gain or loss on financial instruments and iii) share-based compensation expenses, and iv) other items that may arise from time to time. Adjusted EBITDA margin represents Adjusted EBITDA divided by revenue. Order Bookings is the dollar sum of contract values of firm customer contracts. Adjusted Net Income is calculated by adding to and deducting from net income, as applicable, certain expenses, costs, charges or benefits incurred in such period which in management’s view are either not indicative of underlying business performance or impact the ability to assess the operating performance of our business, including i) amortization of intangible assets related to business combinations, ii) unrealized foreign exchange gain or loss, iii) unrealized gain or loss on financial instruments, and iv) share-based compensation expenses, and iv) other items that may arise from time to time. Adjusted Earnings per Share represents Adjusted Net Income divided by the weighted average number of shares outstanding. Order Bookings is indicative of firm future revenues; however, it does not provide a guarantee of future net income and provides no information about the timing of future revenue. Net Debt is the total carrying amount of long-term debt including current portions, as presented in the Q2 2024 Financial Statements, less cash (or plus bank indebtedness) and excluding any lease liabilities. Net Debt is a liquidity metric used to determine how well the Company can pay all of its debts if they were due immediately. Free Cash Flow is a supplemental measure used to monitor the availability of discretionary cash generated, and available to the Company to repay debt, make strategic investments, and meet other payment obligations. We define Free Cash Flow as operating cash flows less net capital expenditures.
FORWARD-LOOKING STATEMENTS
This press release may contain forward‐looking information within the meaning of applicable securities legislation, which reflects the Company’s current expectations regarding future events. Forward‐looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Company’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward‐looking information. Such risks and uncertainties include, but are not limited to the factors discussed under “Risk Factors” in the Company’s Annual Information Form (AIF) dated February 28, 2024 and available on SEDAR+ at www.sedarplus.com. MDA Space does not undertake any obligation to update such forward‐looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
ABOUT MDA SPACE
Building the space between proven and possible, MDA Space (TSX:MDA) is a trusted mission partner to the global space industry. A robotics, satellite systems and geointelligence pioneer with a 55-year+ story of world firsts and more than 450 missions, MDA Space is a global leader in communications satellites, Earth and space observation, and space exploration and infrastructure. The MDA Space team of more than 3,000 space experts in Canada, the US and the UK has the knowledge and know-how to turn an audacious customer vision into an achievable mission – bringing to bear a one-of-a-kind mix of experience, engineering excellence and wide-eyed wonder that’s been in our DNA since day one. For those who dream big and push boundaries on the ground and in the stars to change the world for the better, we’ll take you there. For more information, visit www.mda.space.
MDA Space Ltd.
Unaudited Interim Condensed Statement of Comprehensive Income
For the three and nine months ended September 30, 2024 and 2023
(In millions of Canadian dollars except per share figures)
Three months
ended Sept. 30,
2024
Three months
ended Sept. 30,
2023
Nine months
ended Sept. 30,
2024
Nine months
ended Sept. 30,
2023
Revenue
$
282.4
$
204.7
$
733.5
$
602.6
Cost of revenue
Materials, labour and subcontractors
(197.0)
(138.2)
(502.6)
(394.0)
Depreciation and amortization of assets
(9.7)
(8.8)
(31.1)
(22.4)
Gross profit
75.7
57.7
199.8
186.2
Operating expenses
Selling, general and administration
(18.4)
(17.8)
(57.9)
(52.2)
Research and development, net
(7.2)
(10.4)
(25.0)
(30.8)
Amortization of intangible assets
(11.6)
(11.0)
(35.5)
(34.8)
Share-based compensation
(3.0)
(2.8)
(8.6)
(6.9)
Operating income
35.5
15.7
72.8
61.5
Other income (expenses)
Unrealized gain (loss) on financial instruments
—
1.0
1.2
(0.1)
Foreign exchange gain (loss)
7.2
0.6
8.7
(0.8)
Finance income
2.3
0.3
3.7
0.3
Finance costs
(4.4)
(2.7)
(18.4)
(7.0)
Other income
—
—
6.6
—
Income before income taxes
40.6
14.9
74.6
53.9
Income tax expense
(11.1)
(5.6)
(20.3)
(18.6)
Net income
29.5
9.3
54.3
35.5
Other comprehensive income
Gain (loss) on translation of foreign operations
(0.8)
0.3
(1.0)
—
Gain (loss) on cash flow hedges
(5.1)
2.2
(3.2)
4.1
Remeasurement gain on defined benefit plans
12.7
4.7
12.1
6.4
Total comprehensive income
$
36.3
$
16.5
$
62.2
$
45.8
Earnings per share:
Basic
$
0.25
$
0.08
$
0.45
$
0.30
Diluted
0.24
0.08
0.44
0.29
Weighted-average common shares outstanding:
Basic
120,107,965
119,329,839
119,874,946
119,191,837
Diluted
124,286,353
121,912,874
123,610,686
120,546,321
MDA Space Ltd.
Unaudited Interim Condensed Statement of Financial Position
September 30, 2024
(In millions of Canadian dollars)
As at
September 30, 2024
December 31, 2023
Assets
Current assets:
Cash
$
139.2
$
22.5
Trade and other receivables
143.7
169.5
Unbilled receivables
266.5
183.1
Inventories
10.1
9.9
Income taxes receivable
44.7
47.3
Other current assets
78.9
24.3
683.1
456.6
Non-current assets:
Property, plant and equipment
448.8
369.1
Right-of-use assets
87.2
71.8
Intangible assets
580.5
582.5
Goodwill
441.0
439.8
Deferred income tax assets
14.2
14.9
Other non-current assets
315.0
227.0
1,886.7
1,705.1
Total assets
$
2,569.8
$
2,161.7
Liabilities and shareholders’ equity
Current liabilities:
Accounts payable and accrued liabilities
$
235.2
$
219.1
Income taxes payable
3.1
4.4
Contract liabilities
523.1
76.9
Current portion of net employee benefit payable
48.7
57.4
Current portion of lease liabilities
13.6
10.9
Other current liabilities
1.7
4.5
825.4
373.2
Non-current liabilities:
Net employee defined benefit payable
23.2
22.8
Lease liabilities
90.9
75.2
Long-term debt
293.8
438.9
Deferred income tax liabilities
190.0
180.8
Other non-current liabilities
6.6
6.1
604.5
723.8
Total liabilities
1,429.9
1,097.0
Shareholders’ equity
Common shares
963.6
956.1
Contributed surplus
36.8
31.3
Accumulated other comprehensive income
26.5
18.6
Retained earnings
113.0
58.7
Total equity
1,139.9
1,064.7
Total liabilities and equity
$
2,569.8
$
2,161.7
MDA Space Ltd.
Unaudited Interim Condensed Consolidated Statement of Cash Flows
For the three and nine months ended September 30, 2024 and 2023
(In millions of Canadian dollars)
Three months
ended Sept. 30,
Three months
ended Sept. 30,
Nine months
ended Sept. 30,
Nine months
ended Sept. 30,
2024
2023
2024
2023
Cash flows from operating activities
Net income
$
29.5
$
9.3
$
54.3
$
35.3
Items not affecting cash:
Income tax expense
11.1
5.6
20.3
18.6
Depreciation of property, plant and equipment
4.1
3.5
14.2
9.4
Depreciation of right-of-use assets
2.4
2.5
8.1
6.8
Amortization of intangible assets
14.8
13.8
44.3
41.0
Gain on disposal of assets
—
—
(5.8)
—
Write-down of assets
—
4.8
—
4.8
Share-based compensation expense
2.2
2.8
7.7
6.9
Investment tax credits accrued
(10.5)
(6.0)
(29.7)
(18.7)
Finance costs, net
2.1
2.4
14.7
6.7
Unrealized (gain) loss on financial instruments
—
(1.0)
(1.2)
0.1
Changes in operating assets and liabilities
200.7
(59.9)
315.4
(38.8)
256.4
(22.2)
442.3
72.1
Interest paid
(6.9)
(4.9)
(19.4)
(12.9)
Income tax received (paid)
9.3
(2.9)
9.6
(4.5)
Net cash from operating activities
258.8
(30.0)
432.5
54.7
Cash flows from investing activities
Purchases of property and equipment
(36.8)
(37.1)
(86.4)
(100.7)
Purchase/development of intangible assets
(16.6)
(12.3)
(46.1)
(34.9)
Proceeds from disposal of assets
—
—
7.4
—
Investment in equity securities
—
—
(9.2)
—
Acquisition of subsidiary, net of cash
(4.0)
—
(27.3)
—
Net cash used in investing activities
(57.4)
(49.4)
(161.6)
(135.6)
Cash flows from financing activities
Borrowings from senior credit facility
—
55.0
110.0
90.0
Repayments to senior credit facility
(105.0)
—
(255.0)
(30.0)
Payment of lease liability (principal portion)
(1.6)
(1.7)
(6.1)
(5.6)
Proceeds from stock options exercised
2.2
0.2
3.0
0.6
Net cash provided by financing activities
(104.4)
53.5
(148.1)
55.0
Net decrease in cash
97.0
(25.9)
122.8
(25.9)
Net foreign exchange differences on cash
(4.2)
0.3
(6.1)
—
Cash, beginning of period
46.4
39.0
22.5
39.3
Cash, end of period
$
139.2
$
13.4
$
139.2
$
13.4
RECONCILIATION OF NON-IFRS MEASURES
The following tables provide a reconciliation of net income to EBITDA, adjusted EBITDA, and adjusted net income:
Third Quarters Ended
Nine Months Ended
(in millions of Canadian dollars)
Sept. 30, 2024
Sept. 30, 2023
Sept. 30, 2024
Sept. 30 2023
Net income
$
29.5
$
9.3
$
54.3
$
35.3
Depreciation and amortization of assets
9.7
8.8
31.1
22.4
Amortization of intangible assets related to business combination
11.6
11.0
35.5
34.8
Income tax expense
11.1
5.6
20.3
18.6
Finance income
(2.3)
(0.3)
(3.7)
(0.3)
Finance costs
4.4
2.7
18.4
7.0
EBITDA
$
64.0
$
37.1
$
155.9
$
117.8
Unrealized foreign exchange loss (gain)
(10.7)
(0.9)
(10.4)
2.5
Unrealized (gain) loss on financial instruments
—
(1.0)
(1.2)
0.1
Impairment of long-lived assets
—
4.8
—
4.8
Gain on disposal of assets
—
—
(5.8)
—
Share-based compensation
2.2
2.8
7.7
6.9
Adjusted EBITDA
$
55.5
$
42.8
$
146.2
$
132.1
Third Quarters Ended
Nine Months Ended
(in millions of Canadian dollars)
Sept. 30, 2024
Sept. 30, 2023
Sept. 30, 2024
Sept. 30, 2023
Net Income
$ 29.5
$ 9.3
$ 54.3
$ 35.3
Amortization of intangible assets related to business combination
11.6
11.0
35.5
34.8
Impairment of long-lived assets
—
4.8
—
4.8
Gain on disposal of assets
—
—
(5.8)
—
Unrealized (gain) loss on financial instruments
—
(1.0)
(1.2)
0.1
Net foreign exchange (gain) loss
(7.2)
(0.6)
(8.7)
0.8
Embedded derivative effects
0.5
—
2.2
—
Share-based compensation
2.2
2.8
7.7
6.9
Income taxes related to the above items3
(1.9)
(4.6)
(8.0)
(12.6)
Adjusted Net income
$ 34.7
$ 21.7
$ 76.0
$ 70.1
Weighted average number of shares outstanding – diluted
124,286,353
121,912,874
123,610,686
120,546,321
Adjusted EPS – diluted
$ 0.28
$ 0.18
$ 0.61
$ 0.58
3 Standard income tax rate of 26.5% applied
View original content to download multimedia:https://www.prnewswire.com/news-releases/mda-space-reports-third-quarter-2024-results-302306490.html
SOURCE MDA Space
Technology
Velotric Launches Black Friday and Cyber Week E-bike Deals – Save Up to $600! Plus, Exclusive Discounts on Accessories
Published
1 minute agoon
November 15, 2024By
Velotric is Offering Amazing Limited-Time Savings on High-Performance E-bikes and Gear, with Special Pricing on Top Models and Essential Cycling Accessories This Holiday Season
CARSON, Calif., Nov. 15, 2024 /PRNewswire/ — Velotric, a rapid leader in the e-bike market, renowned for their effortlessly comfortable e-bikes with their ComfortMax technology that deliver outstanding performance, top-tier safety, and a user-focused design, is excited to unveil their Black Friday and Cyber Week promotions, giving customers remarkable savings on their high-performance e-bikes.
Starting today, Velotric is offering shoppers exclusive discounts of up to $600 off their most popular models. This sale is one of Velotric’s biggest of the year, providing an ideal opportunity for riders to elevate their biking experience with savings on everything from urban commuter bikes to rugged adventure models. Discounts will be automatically applied at checkout.
“Over the past two years, Velotric has empowered over 100,000 riders to log more than 50 million miles of reliable, sustainable transportation, offering a cleaner commuting option that reduces their carbon footprint,” said Adam Zhang, Co-founder and CEO of Velotric. “We’re proud to help people rethink their daily travel while making a positive impact on the environment.”
Black Friday Prelaunch: November 15 – November 28:
Discover 2 (Premium Commuter) – $150 offSale Price: $1,749Summit 1 (Hybrid E-Mountain Bike) – $150 offSale Price: $1,849Discover 1+ (Urban Commuter) – $500 offSale Price: $1,099Nomad 1+ (Fat Tire) – $500 offSale Price: $1,299T1 ST+ (Better for Exercise) – $350 offSale Price: $1,199Fold 1 (Folding E-Bike) – $300 offSale Price: $1,099Get 3 accessories & unlock 30% Off – on select accessories
Buy TWO Save up to $400: November 22 – November 28:
$150 off the Discover 2 and Summit 1; buy 2 and get an additional $100 off (total saving $400)
Limited 100 @ $999: November 22 – December 8:
Fold 1 Lite (Compact, Folding E-Bike) – $100 offSale Price: $999 (Only 100 units first come, first serve)30% Off select accessories when you buy 3
BLACK FRIDAY & CYBER WEEK: November 29 – December 5
Discover 2 (Premium Commuter) – $150 Off (Buy 2 get an extra $100 off)Sale Price: $1,749Summit 1 (Hybrid eMountain Bike) – $150 Off (Buy 2 get an extra $100 off)Sale Price: $1,849Discover 1+ (Urban Commuter) – $400 OffSale Price: $1,199Nomad 1+ (Fat Tire) – $400 OffSale Price: $1,399T1 ST+ (Better for Exercise) – $250 OffSale Price: $1,299Fold 1 (Folding E-Bike) – $200 OffSale Price: $1,199Go 1 (Compact Utility) – $400 OffSale Price: $1,299Packer 1 (Heavy-Duty Cargo) – $600 OffSale Price: $1,59950% Off on select accessoriesUnlock free additional 1-year extended warranty (3 years in total)
Post-Black Friday & Cyber Week: December 6 – December 8
Discover 2 (Premium Commuter) – $150 OffSale Price: $1,749Summit 1 (Hybrid Multi Terrain) – $150 OffSale Price: $1,849Discover 1+ (Urban Commuter) – $400 OffSale Price: $1,199Nomad 1+ (Fat Tire) – $400 OffSale Price: $1,399T1 ST+ (E-Bike for Better Exercise) – $250 OffSale Price: $1,299Fold 1 (Folding E-Bike) – $200 OffSale Price: $1,199Go 1 (Compact Utility) – $300 OffSale Price: $1,399Packer 1 (Heavy-Duty Cargo) – $500 OffSale Price: $1,69930% Off select accessories
For more details on deals, discounts, and extended holiday offers, visit Velotric’s website at Velotricbike.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/velotric-launches-black-friday-and-cyber-week-e-bike-deals–save-up-to-600-plus-exclusive-discounts-on-accessories-302306545.html
SOURCE Velotric
Nuvilab: Advancing School Nutrition with AI-Powered Nutrition Coaching, Wins CES 2025 Innovation Award
MDA SPACE REPORTS THIRD QUARTER 2024 RESULTS
Velotric Launches Black Friday and Cyber Week E-bike Deals – Save Up to $600! Plus, Exclusive Discounts on Accessories
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
Peloton Unveils Holiday 2022 Creative Campaign Highlighting How Motivation Transcends Beyond the Workout
These ’90s fashion trends are making a comeback in 2017
Why You Should Build on #NEAR – Co-founder Illia Polosukhin at CV Labs
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
NEAR End of Year Town Hall 2021: The Open Web World, MetaBUILD 2 Hackathon and 2021 recap
Trending
-
Technology5 days ago
Decode economic ties between GBA and Colombia from a cup of coffee
-
Coin Market5 days ago
Near plans to build world’s largest 1.4T parameter open-source AI model
-
Technology5 days ago
SGT25 draw together 400+ European power grid technical professionals for a review of the latest grid transformation projects
-
Coin Market5 days ago
Snowden calls for decentralization, criticizes VC influence on Solana
-
Technology5 days ago
Cangzhou Forum Seeks to Deepen Ties Between Chinese and Central/Eastern European SMEs
-
Coin Market5 days ago
WalletConnect Foundation and Reown establish UX standards framework
-
Near Videos5 days ago
[REDACTED] Day 2 | NEAR is the Blockchain for AI
-
Technology3 days ago
XChange TEC.INC RECEIVES NASDAQ MINIMUM BID PRICE DEFICIENCY NOTICE